Molecular Formula | C29H34BrNO2 |
Molar Mass | 508.48976 |
Melting Point | >231°C (dec.) |
Solubility | DMSO (Slightly), Methanol (Slightly), Water (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
Stability | Hygroscopic |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.967 ml | 9.833 ml | 19.666 ml |
5 mM | 0.393 ml | 1.967 ml | 3.933 ml |
10 mM | 0.197 ml | 0.983 ml | 1.967 ml |
5 mM | 0.039 ml | 0.197 ml | 0.393 ml |
COPD drug | umeclidinium bromide was developed by GlaxoSmithKline (GSK), first approved for marketing by Health Canada on April 17, 2014, then approved by the European Medicines Agency (EMA) on April 28, it was later approved for marketing by the U. S. Food and Drug Administration (FDA) on 4/30/2014 and then approved by the Japanese medical and medical device administration (PMDA) on 3/26/2015. Marketed by GSK under the trade name Incruse Ellipta®, Incruse®And Encruse®. umeclidinium bromide is a long-acting, competitive and reversible muscarinic choline receptor antagonist (mAChRs) that maintains bronchodilation. The drug is indicated for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Incruse Ellipta®It is an inhalable powder containing 62.5 μg of umeclidinium bromide. The recommended dose is 62.5 μg per inhalation (1 inhalation), once daily. |
mechanism of action | umeclidinium bromide is a long-acting choline receptor antagonist (LAMA) that relaxes bronchial smooth muscle. The kinetic selectivity for the M3 receptor is higher than for the M2 receptor, with slower dissociation with the M3 receptor than with m2. And has the effect of anti parasympathetic nerve, can inhibit the role of M3 receptor. |
synthetic routes |